Trial · NCT06907342
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. | Up to 1 month | Rate of generating valid\* tumouroid response reports per patient included in the trial. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with respect to day 0 or 1. |
| Primary | Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. | Up to 1 month | Rate of generating valid\* tumouroid response reports per patient with obtained tumour sample. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with resepect to day 0 or 1. |
| Primary | Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. | Up to 1 month | What is the time from referral to start of allocated treatment |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Objective Response Rate (ORR) |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Disease Control Rate (DCR) |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Clinical Benefit Rate (CBR), defined as the percentage of patients who had a complete response, partial response, or had stable disease for 6 months or more |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Duration of Response (DoR) |
| Secondary | Assess progression free survival | Up to 5 years | Progression Free Survival (PFS), defined as the time from starting first-line treatment to the time of documentation of progressive disease (PD) according to RECIST v.1.1 on active therapy, determined failure of treatment strategy or death |
| Secondary | Assess progression free survival rate | Up to 6 months | Progression Free Survival Rate (PFSR), defined as the ratio of participants with PFS at 6 months |
| Secondary | Assess overall survival | Up to 5 years | Overall Survival |
| Secondary | Toxicity experienced in the trial | Up to 2 years | Incidence of grade 3-5 adverse events using CTCAE v.5.0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06907342/registered